Compare CAPT & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPT | ELUT |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1M | 25.2M |
| IPO Year | N/A | 2020 |
| Metric | CAPT | ELUT |
|---|---|---|
| Price | $0.63 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.3M | 250.4K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $17,389,944.00 | ★ $21,746,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 84.70 | 24.08 |
| 52 Week Low | $0.37 | $0.58 |
| 52 Week High | $1.94 | $4.84 |
| Indicator | CAPT | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 37.87 | 42.36 |
| Support Level | $0.71 | $0.60 |
| Resistance Level | $0.88 | $0.72 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 6.95 | 49.91 |
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.